Opiant developed the NARCAN® Nasal Spray. This product, licensed to Adapt (now a part of Emergent BioSolutions) in 2014, was FDA approved in late 2015. In just over three years, NARCAN® Nasal Spray has become the most widely used naloxone product in the United States.
We are also developing OPNT003, a nalmefene nasal spray for the treatment of suspected or confirmed opioid overdose. Nalmefene, an opioid antagonist previously FDA approved as an injection, is more potent and longer-acting than naloxone. This product candidate is being developed in response to the dramatic rise in fatalities due to high potency ‘synthetic’ opioids such as fentanyl, where a more potent, longer-lasting opioid antagonist may increase the probability of a successful rescue.
We are developing OPNT002, a naltrexone nasal spray for the treatment of Alcohol Use Disorder (AUD).